Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study

BackgroundPre-clinical and clinical evidences support that simultaneous blockade of programmed death-1 (PD-1) and vascular endothelial growth factor receptor (VEGFR) can enhance antigen-specific T-cell migration, and show tolerable toxicity with favorable antitumor activity in patients. In this stud...

Full description

Bibliographic Details
Main Authors: Peiliang Wang, Xiaozhuang Fang, Tianwen Yin, Hairong Tian, Jinming Yu, Feifei Teng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
anlotinib
anti-PD-1
non–small cell lung cancer
combination therapy
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.628124/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.628124/full

Similar Items